Pregabalin Capsule
Product Images NDC 71335-2339

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-2339). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713352339)

Pregabalin Capsules 75 mg oral capsules label showing NDC 71335-2339-1. The label states the package contains 30 capsules and is repackaged by Bryant Ranch Prepack, Inc. It includes storage instructions, child-resistant container warning, and references the Medication Guide URL. Manufactured by ScieGen Pharmaceuticals, Inc.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph depicting the percentage of patients improved relative to percent improvement in pain from baseline for Pregabalin at doses of 25 mg, 100 mg, and 200 mg taken three times a day, compared to placebo. The y-axis shows the percent of patients improved, and the x-axis represents percent improvement in pain from baseline. Higher doses generally show higher patient improvement rates.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line chart comparing percent of patients improved versus percent improvement in pain from baseline. It displays two curves labeled Pregabalin 100 mg three times a day and Placebo, showing higher improvement rates for Pregabalin across percent improvement levels.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line chart showing percent of patients improved plotted against percent improvement in pain from baseline. It compares Pregabalin at 75 mg, 150 mg, and 300 mg taken two times daily, along with a placebo group, illustrating varying levels of patient improvement percentages across the different treatments.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for pregabalin 200 mg three times a day, pregabalin 100 mg three times a day, and placebo. The graph shows higher pain improvement percentages for pregabalin groups compared to placebo over increasing pain improvement thresholds.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating differences in pain improvement percentages across these treatments.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

Bar graph showing responder rates (%) for Pregabalin treatment vs placebo in two clinical studies, E1 and E3. Study E1 compares placebo and doses from 50 mg/day to 600 mg/day BID, with increasing responder rates up to 51%. Study E3 compares placebo with 300 mg/day BID and 600 mg/day TID, showing responder rates of 9%, 43%, and 49%, respectively. Statistical significance is noted for treatment groups versus placebo.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph showing seizure reduction (median % change from baseline) versus dose (mg/day) for studies labeled E1, E2, and E3 with different dosing schedules (BD and TID). The graph includes data points with statistical significance p-values indicated, comparing doses ranging from 0 to 600 mg/day. A note states that a dose of 0 represents placebo and only significant p-values are displayed.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph depicting percent improvement in pain from baseline on the x-axis against percent of patients improved on the y-axis. Four lines compare Pregabalin daily doses of 300 mg, 450 mg, and 800 mg with placebo, showing variations in patient improvement percentages across the dose levels.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing the estimated percentage of subjects without LTR (treatment response) over 180 days between Pregabalin and placebo groups. The y-axis represents the estimated percentage without LTR from 0% to 100%, and the x-axis shows days from 0 to 180. The Pregabalin group shows a higher percentage over time compared to placebo, with solid and dashed lines representing Pregabalin and placebo, respectively.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over the percent improved from baseline to week 12 BOCF for Pregabalin versus placebo. The vertical axis shows percent of subjects improved (0-100%) and the horizontal axis shows percent improved from baseline to week 12 BOCF (0-100%). Pregabalin shows a consistently higher percent improvement across the range compared to placebo.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved on the y-axis against the percent improvement from baseline to week 16 BOCF on the x-axis (ranging from 0 to 100). Two lines represent Pregabalin (solid line) and Placebo (dashed line), showing improvement percentages for each treatment group over the range.*

FDA Label Image

Figure 13 (Pregabalin Fig13)

A bar graph depicting responder rates (%) for three groups: Placebo, 2.5 mg/kg/day, and 10 mg/kg/day. The responder rate increases from 22.6% for Placebo (n=93) to 29.1% for 2.5 mg/kg/day (n=103) and 40.6% for 10 mg/kg/day (n=96). The y-axis represents responder rate percentage and the x-axis shows treatment groups with sample sizes.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A formula describing creatinine clearance (CLcr) calculation, using age in years, weight in kilograms, serum creatinine in mg/dL, and an adjustment factor of 0.85 for female patients.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of pregabalin, showing its molecular arrangement including an amine group, carboxyl group, and side chains consistent with the 75 mg capsule formulation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.